Nav: Home

How understanding the dynamics of yeast prions can shed light on neurodegenerative diseases

April 06, 2020

Prions are a class of misfolded proteins that form aggregates called "amyloid fibrils." These aggregates are the main culprit behind severe mammalian neurodegenerative diseases like Alzheimer's. What makes them so deadly is that they are capable of transmitting their erroneous conformation to otherwise healthy proteins, causing an imbalance in cellular function. Currently, there are no effective treatments for fatal prion diseases, mainly because studying mammalian prions is challenging. Thus, scientists have turned to studying prions in less complex organisms like yeast, which could give us more insight about mammalian prions. Yeast prions, such as the protein Sup35NM, are also known to form amyloid fibrils. But, the process by which individual Sup35NM molecules, called monomers, combine to form amyloid fibrils is not yet understood. Moreover, Sup35NM monomers sometimes form smaller structures called oligomers--another process that remains unclear. To shed light on prion-related diseases, it is crucial to understand the exact details of how amyloid fibrils are formed from prions.

In a new study published in PNAS, researchers from Tokyo Institute of Technology and Kanazawa University, led by Prof Hideki Taguchi, set out to dig deeper into prion structures and their mechanisms. They used a modern microscopy technique, called high-speed atomic force microscopy (HS-AFM), developed by Dr. Toshio Ando at Kanazawa University, to visualize the formation of Sup35NM amyloid fibrils in real time. Prof Taguchi explains, "Previous studies used methods that do not allow for the simultaneous, high-resolution assessment of the structures and dynamics involved in Sup35NM oligomerization and fibrillation. To overcome this limitation, we used HS-AFM, which allows the direct visualization of protein molecules in dynamic action at a high resolution."

To begin with, the researchers analyzed Sup35NM monomers using HS-AFM. Their analysis revealed that Sup35NM molecules contained a globular structure with two highly flexible tail-like structures. Then, to observe the oligomeric forms of Sup35NM, monomers incubated in a denaturing solution in controlled conditions, which, in a few hours, led to the formation of oligomers. Further HS-AFM analyses revealed the exact size of these oligomers--a maximum of 3-4 nm, not growing any longer than this. Thus, the scientists inferred that this size could be an inherent property of oligomers under these conditions.

The researchers then moved on to study the fibril forms of Sup35NM. As opposed to oligomers, fibrils required much a longer incubation time to form, typically 2 to 3 days. In addition, the researchers observed that the fibril elongated smoothly without the attachment of the oligomers. These findings indicated that Sup35NM oligomers are not a prerequisite for the formation of amyloid fibrils, leading the scientists to conclude that oligomers might actually possess cellular functions that are different from those of Sup35NM.

Finally, the researchers studied an interesting phenomenon where oligomers and fibril structures seem to maintain an interspatial distance or "gap." They observed that the trunk of the fibrils has a rigid structure that repels oligomers coming from the sides. Meanwhile, the gap between the tip of the fibril and nearby oligomers is less pronounced because the tip does not have such rigid structures. This helped the scientists understand why Sup35NM amyloid fibrils always grow in a straight direction, without forming any branches.

In sum, these findings provide a detailed account into the structural and functional characteristics of yeast prions--in their monomeric, oligomeric, and fibril forms. "Our HS-AFM observations of Sup35NM unveiled features of Sup35NM dynamics, providing mechanistic insight into amyloid fibril formation," concludes Prof Taguchi.

Does this new insight into the structure and mechanism of prions bring hope for effective therapies against neurodegenerative diseases in humans? Only time will tell, but this study surely takes a huge step towards that direction.
-end-


Tokyo Institute of Technology

Related Neurodegenerative Diseases Articles:

First 'pathoconnectome' could point toward new treatments for neurodegenerative diseases
Scientists from the John A. Moran Eye Center at the University of Utah have achieved another first in the field of connectomics, which studies the synaptic connections between neurons.
Unlocking the mystery of tau for treatment of neurodegenerative diseases
A team of researchers from various collaborating universities and hospitals in Japan has uncovered crucial molecular details regarding the activity of the ''tau'' protein, promising to revolutionize the therapy of tau-induced neurodegenerative diseases.
Investigational drug stops toxic proteins tied to neurodegenerative diseases
An investigational drug that targets an instigator of the TDP-43 protein, a well-known hallmark of amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD), may reduce the protein's buildup and neurological decline associated with these disorders, suggests a pre-clinical study from researchers at Penn Medicine and Mayo Clinic.
Inhibition of sphingolipid metabolism and neurodegenerative diseases
Disrupting the production of a class of lipids known as sphingolipids in neurons improved symptoms of neurodegeneration and increased survival in a mouse model.
How understanding the dynamics of yeast prions can shed light on neurodegenerative diseases
How understanding the dynamics of yeast prions can shed light on neurodegenerative diseases
New family of molecules to join altered receptors in neurodegenerative diseases
An article published in the Journal of Medicinal Chemistry shows a new family of molecules with high affinity to join imidazoline receptors, which are altered in the brain of those patients with neurodegenerative diseases such as Alzheimer's, Parkinson's and Huntington's.
Examining diagnoses of stress-related disorders, risk of neurodegenerative diseases
Researchers investigated how stress-related disorders (such as posttraumatic stress disorder, adjustment disorder and stress reactions) were associated with risk for neurodegenerative diseases, including Alzheimer and Parkinson disease and amyotrophic lateral sclerosis (ALS), using data from national health registers in Sweden.
Toxic protein, linked to Alzheimer's and neurodegenerative diseases, exposed in new detail
The protein tau has long been implicated in Alzheimer's and a host of other debilitating brain diseases.
Study uncovers unexpected connection between gliomas, neurodegenerative diseases
New basic science and clinical research identifies TAU, the same protein studied in the development of Alzheimer's, as a biomarker for glioma development.
Neurodegenerative diseases may be caused by transportation failures inside neurons
Protein clumps are routinely found in the brains of patients with neurodegenerative diseases.
More Neurodegenerative Diseases News and Neurodegenerative Diseases Current Events

Trending Science News

Current Coronavirus (COVID-19) News

Top Science Podcasts

We have hand picked the top science podcasts of 2020.
Now Playing: TED Radio Hour

Listen Again: The Power Of Spaces
How do spaces shape the human experience? In what ways do our rooms, homes, and buildings give us meaning and purpose? This hour, TED speakers explore the power of the spaces we make and inhabit. Guests include architect Michael Murphy, musician David Byrne, artist Es Devlin, and architect Siamak Hariri.
Now Playing: Science for the People

#576 Science Communication in Creative Places
When you think of science communication, you might think of TED talks or museum talks or video talks, or... people giving lectures. It's a lot of people talking. But there's more to sci comm than that. This week host Bethany Brookshire talks to three people who have looked at science communication in places you might not expect it. We'll speak with Mauna Dasari, a graduate student at Notre Dame, about making mammals into a March Madness match. We'll talk with Sarah Garner, director of the Pathologists Assistant Program at Tulane University School of Medicine, who takes pathology instruction out of...
Now Playing: Radiolab

What If?
There's plenty of speculation about what Donald Trump might do in the wake of the election. Would he dispute the results if he loses? Would he simply refuse to leave office, or even try to use the military to maintain control? Last summer, Rosa Brooks got together a team of experts and political operatives from both sides of the aisle to ask a slightly different question. Rather than arguing about whether he'd do those things, they dug into what exactly would happen if he did. Part war game part choose your own adventure, Rosa's Transition Integrity Project doesn't give us any predictions, and it isn't a referendum on Trump. Instead, it's a deeply illuminating stress test on our laws, our institutions, and on the commitment to democracy written into the constitution. This episode was reported by Bethel Habte, with help from Tracie Hunte, and produced by Bethel Habte. Jeremy Bloom provided original music. Support Radiolab by becoming a member today at Radiolab.org/donate.     You can read The Transition Integrity Project's report here.